ClinicalTrials.gg
CompletedNCT00755781CIS001Updated Sep 17, 2012

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

A Phase 3 interventional study of Cyclosporine Inhalation Solution (CIS) in Lung Transplant, sponsored by APT Pharmaceuticals, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-17.

Sponsored by APT Pharmaceuticals, Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Enrollment
35th of 260
284 · median 45
Started
2008
with 12 others
Phase 3
30 of 300
4 open now
Registered
48th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 35th largest by enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2008, is one of 30 in phase 3, and was the 48th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Phase III, multi-center, randomized, controlled study designed to demonstrate the efficacy and safety of Cyclosporine Inhalation Solution (CIS)in improving survival and preventing bronchiolitis obliterans syndrome (BOS) when given prophylactically to lung transplant recipients in addition to their standard immunosuppressive regimen.

03

Conditions studied

  • Lung Transplant

Keywords

  • lung transplant
  • lung transplant recipient
  • bronchiolitis obliterans syndrome
  • bronchiolitis obliterans
  • single lung transplant
  • double lung transplant
  • heart-lung transplant
  • Aerosol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A recipient of a single or double lung transplant (including heart-lung transplant)
  • Age 18 years or older
  • Able to produce a (FEV1) of greater than one liter at randomization
  • Eligible subjects must be enrolled within 70 days after receiving a lung transplant
  • Clinical status sufficiently stable to enable routine post-transplant bronchoscopy with bronchoalveolar lavage (BAL) and chest X-ray (or equivalent i.e., chest computerized tomogram (CT)) prior to screening

Exclusion criteria

Exclusion Criteria:

  • Lung re-transplantation
  • Documented allergy to propylene glycol and/or cyclosporine
  • Documented respiratory or anastomotic infections unless on appropriate antimicrobial therapy with evidence of clinical response
  • Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate to avoid becoming pregnant
  • Women who are breastfeeding
  • bronchial stenosis unresponsive to dilation and/or stenting
  • diagnosed within one year prior to screening (with the exception of non-melanomatous skin cancers)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Active comparator
    CIS

    CIS in addition to standard immunosuppressive regimen.

    Drug: Cyclosporine Inhalation Solution (CIS)

  • No intervention
    SOC

    Standard of care (SOC) therapy for lung transplant recipients

Interventions

  • Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)

    Also known as: Cyclosporine

06

What researchers measure

Primary outcomes

  1. Duration of BOS-free survival. Other causes for the decline should be excluded by bronchoscopy and other diagnostic testing performed at the discretion of the investigator. The diagnosis of BOS will be determined by the Outcomes Committee

    Time frame: Assessed when symptoms of syndrome present

Secondary outcomes

  1. Pulmonary function as measured by mean FEV1 percent predicted at 2 years after randomization

    Time frame: From study initiation through 2+ years after randomization

  2. All cause mortality

    Time frame: From study initiation through 2+ years after randomization

  3. Duration of event-free survival, corresponding to the length of time between date of randomization and either death or the occurrence of serious bacterial and viral infections that start in the lungs (defined by reporting of a SAE)

    Time frame: From study initiation through 2+ year after randomzation

07

Study locations

19 sites
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • University of Florida Health Sciences Center
    Gainesville, Florida 32610, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Tampa General Hospital
    Tampa, Florida 33601, United States
  • University of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Loyola University Hospital
    Maywood, Illinois 60153, United States
  • Indiana Methodist Research Institute
    Indianapolis, Indiana 46202, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • New York Presbyterian Hospital, Columbia University Med. Ctr.
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22402, United States
  • University of Toronto
    Toronto, Ontario M5G 2N2, Canada
08

References and documents

Publications

  • Burkart GJ, Smaldone GC, Eldon MA, Venkataramanan R, Dauber J, Zeevi A, McCurry K, McKaveney TP, Corcoran TE, Griffith BP, Iacono AT. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res. 2003 Feb;20(2):252-6. doi: 10.1023/a:1022275222207. PubMed 12636164 ↗
  • Iacono AT, Smaldone GC, Keenan RJ, Diot P, Dauber JH, Zeevi A, Burckart GJ, Griffith BP. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med. 1997 May;155(5):1690-8. doi: 10.1164/ajrccm.155.5.9154878. PubMed 9154878 ↗
  • Keenan RJ, Iacono A, Dauber JH, Zeevi A, Yousem SA, Ohori NP, Burckart GJ, Kawai A, Smaldone GC, Griffith BP. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997 Feb;113(2):335-40; discussion 340-1. doi: 10.1016/S0022-5223(97)70331-3. PubMed 9040628 ↗
  • Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, Yousem S, Williams P, Griffith B, Zeevi A. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation. 1997 Jul 27;64(2):263-9. doi: 10.1097/00007890-199707270-00015. PubMed 9256185 ↗
  • Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12;354(2):141-50. doi: 10.1056/NEJMoa043204. PubMed 16407509 ↗
  • Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, Smaldone GC, McCurry KR, Johnson BA, Dauber JH. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004 Mar;23(3):384-90. doi: 10.1183/09031936.04.00058504. PubMed 15065826 ↗
  • Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, Griffith BP. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1451-5. doi: 10.1164/ajrccm.153.4.8616581. PubMed 8616581 ↗
  • Corcoran TE, Niven R, Verret W, Dilly S, Johnson BA. Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. J Aerosol Med Pulm Drug Deliv. 2014 Jun;27(3):178-84. doi: 10.1089/jamp.2013.1042. Epub 2013 May 13. PubMed 23668548 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Sep 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 19, 2008
Start
Sep 2008
Primary completionActual
Sep 2011
CompletionActual
Nov 2011
Last update
Sep 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00755781
Lead sponsor
APT Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2008
Start date
Sep 2008
Primary completion
Sep 2011
Completion
Nov 2011
Last update
Sep 17, 2012

Study contacts

Stephen Dilly, MD PhD
study director · APT Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion